American Oncology Network, Inc.

AONC SEC CIK 0001839998 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$336.36M
Covers every share class this company has on file.
Insiders on file
3
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$15.23M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
4.53%
insider-held value divided by market capitalisation

What American Oncology Network, Inc. reports

Revenue and net income below are for fiscal period FY2024, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$1.76B
FY2024 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$26.96M
FY2024 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
1,914
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at American Oncology Network, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against American Oncology Network, Inc..
Insider Reported role Shares Value Last action
Officers 1
David Afshar CFO 150,000 $1.50M A Grant or award Jul 16, 2024 position reported
Officers who also sit on the board 2
Todd Schonherz CEO 1,174,799 $11.74M A Grant or award Jul 16, 2024 position reported
Stephen Divers Other Executive 199,826 $2.00M A Grant or award Jul 16, 2024 position reported

Recent insider transactions

Of the 7 rows we hold, 4 are open-market purchases (P) and 0 open-market sales — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for American Oncology Network, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jul 16, 2024 Todd Schonherz A Grant or award 300,000 $0.00 $0 SEC filing ↗
Jul 16, 2024 Stephen Divers A Grant or award 36,000 $0.00 $0 SEC filing ↗
Jul 16, 2024 David Afshar A Grant or award 150,000 $0.00 $0 SEC filing ↗
May 24, 2024 Stephen Divers P Open-market purchase 5,000 $2.15 $10.8K SEC filing ↗
May 21, 2024 Todd Schonherz P Open-market purchase 4,000 $1.87 $7.5K SEC filing ↗
May 21, 2024 Todd Schonherz P Open-market purchase 1,000 $1.85 $1.9K SEC filing ↗
May 21, 2024 Todd Schonherz P Open-market purchase 340 $1.86 $632 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.